AtriCure (ATRC) Stock Price
AtriCure Price
Revenue has compounded at 14.9% per year over the past 19 years to 534.53 M USD. AtriCure's net margin stands at -2.1%, down from 18.3% several years earlier. Analysts set a median price target of 52.00 USD, implying 10.5% below the current price. Of 16 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 127% above its 52-week low.
AtriCure stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of AtriCure over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how AtriCure stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing AtriCure's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | AtriCure Price |
|---|---|
| 9/18/2026 | 58.10 USD |
| 9/17/2026 | 59.12 USD |
| 9/16/2026 | 57.09 USD |
| 9/15/2026 | 55.55 USD |
| 9/14/2026 | 55.79 USD |
| 9/13/2026 | 55.79 USD |
| 9/11/2026 | 54.16 USD |
| 9/10/2026 | 52.96 USD |
| 9/9/2026 | 53.03 USD |
| 9/8/2026 | 52.06 USD |
| 9/4/2026 | 51.52 USD |
| 9/3/2026 | 52.46 USD |
| 9/2/2026 | 52.59 USD |
| 9/1/2026 | 48.92 USD |
| 8/31/2026 | 48.35 USD |
| 8/30/2026 | 48.07 USD |
| 8/28/2026 | 49.13 USD |
| 8/27/2026 | 48.68 USD |
| 8/26/2026 | 48.17 USD |
| 8/25/2026 | 48.68 USD |
| 8/24/2026 | 49.15 USD |
| 8/21/2026 | 48.98 USD |
| 8/20/2026 | 47.49 USD |
| 8/19/2026 | 47.49 USD |
| 8/18/2026 | 45.83 USD |
| 8/14/2026 | 44.30 USD |
| 8/13/2026 | 43.49 USD |
| 8/12/2026 | 43.56 USD |
| 8/11/2026 | 42.95 USD |
| 8/10/2026 | 41.83 USD |
AtriCure Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
AtriCure Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 129.00 | 155.00 | 174.00 | 201.00 | 230.00 | 206.00 | 274.00 | 330.00 | 399.00 | 465.00 | 534.00 | 606.00 | 679.00 | 764.00 | 850.00 | 977.00 |
| 20.56 | 20.16 | 12.26 | 15.52 | 14.43 | -10.43 | 33.01 | 20.44 | 20.91 | 16.54 | 14.84 | 13.48 | 12.05 | 12.52 | 11.26 | 14.94 |
| 71.32 | 71.61 | 72.41 | 73.13 | 73.91 | 72.33 | 74.82 | 74.24 | 75.19 | 74.62 | 74.34 | 74.34 | 74.34 | 74.34 | 74.34 | 74.34 |
| 92.00 | 111.00 | 126.00 | 147.00 | 170.00 | 149.00 | 205.00 | 245.00 | 300.00 | 347.00 | 397.00 | 450.53 | 504.80 | 567.99 | 631.93 | 726.35 |
| -26.00 | -31.00 | -24.00 | -17.00 | -33.00 | -44.00 | 55.00 | -43.00 | -26.00 | -41.00 | -3.00 | 12.00 | 33.00 | 50.00 | 50.00 | 69.00 |
| -20.16 | -20.00 | -13.79 | -8.46 | -14.35 | -21.36 | 20.07 | -13.03 | -6.52 | -8.82 | -0.56 | 1.98 | 4.86 | 6.54 | 5.88 | 7.06 |
| -27.00 | -33.00 | -26.00 | -21.00 | -35.00 | -48.00 | 50.00 | -46.00 | -30.00 | -44.00 | -11.00 | 5.00 | 20.00 | 34.00 | 36.00 | 52.00 |
| 68.75 | 22.22 | -21.21 | -19.23 | 66.67 | 37.14 | -204.17 | -192.00 | -34.78 | 46.67 | -75.00 | -145.45 | 300.00 | 70.00 | 5.88 | 44.44 |
| 30.63 | 31.79 | 32.65 | 36.48 | 38.19 | 44.12 | 45.33 | 45.91 | 46.45 | 47.11 | 48.87 | 48.87 | 48.87 | 48.87 | 48.87 | 48.87 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales AtriCure generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue AtriCure retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare AtriCure's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares AtriCure has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against AtriCure's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
AtriCure stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
AtriCure Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
AtriCure business model & stock analysis
AtriCure Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
AtriCure Segments
AtriCure Revenue by Segment (1/4)
3 Years
5 Years
Max
Details
AtriCure Revenue by Segment (2/4)
3 Years
5 Years
Max
Details
AtriCure Revenue by Segment (3/4)
3 Years
5 Years
10 Years
Max
Details
AtriCure Revenue by Segment (4/4)
3 Years
Max
Details
AtriCure Revenue by Region
3 Years
5 Years
10 Years
Max
Details
AtriCure Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
AtriCure historical P/E ratio, EBIT multiple, and P/S ratio
AtriCure annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down AtriCure's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in AtriCure's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare AtriCure's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
AtriCure shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current AtriCure forecasts and price targets in September 2026
Analyst Price Targets 2026AtriCure Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 7/28/2026 | Maintained | Buy | 49 | |
| 5/6/2026 | Maintained | Buy | 63 | |
| 2/18/2026 | Maintained | Buy | 49 | |
| 2/18/2026 | Downgrade | OutperformPerform | 61 | |
| 2/18/2026 | Maintained | Market Outperform | – | |
| 2/18/2026 | Maintained | Buy | 63 | |
| 2/18/2026 | Maintained | Buy | 49 | |
| 2/12/2026 | Maintained | Buy | 58 | |
| 12/16/2025 | Maintained | Overweight | 53 | |
| 10/30/2025 | Maintained | Buy | 63 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
AtriCure Earnings Calls
AtriCure Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/4/2026 | 0.01USD | - | 151.18 MUSD | - | 2026 Q3 |
| 7/23/2026 | -0.00USD | 0.18USD | 151.80 MUSD | - | 2026 Q2 |
| 5/5/2026 | -0.07USD | 0.00USD | 139.75 MUSD | - | 2026 Q1 |
| 2/17/2026 | -0.04USD | 0.06USD | 139.71 MUSD | - | 2025 Q4 |
| 10/29/2025 | -0.11USD | -0.01USD | 140.50 MUSD | - | 2025 Q3 |
| 7/29/2025 | -0.15USD | -0.13USD | 130.18 MUSD | - | 2025 Q2 |
| 4/29/2025 | -0.25USD | -0.14USD | 130.60 MUSD | - | 2025 Q1 |
| 2/12/2025 | -0.23USD | -0.33USD | 121.25 MUSD | - | 2024 Q4 |
| 10/29/2024 | -0.20USD | -0.17USD | 119.85 MUSD | - | 2024 Q3 |
| 7/30/2024 | -0.15USD | -0.17USD | 116.18 MUSD | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the AtriCure stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
AtriCure shareholder structure
| % | Name |
|---|---|
8.13090% | |
6.80321% | |
6.55445% | |
6.27020% | |
5.43570% | |
4.33581% |
AtriCure Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
11.20% | SEC ↗ | |
9.22% | SEC ↗ | |
8.32% | SEC ↗ | |
8.10% | SEC ↗ | |
8.02% | SEC ↗ | |
8.02% | SEC ↗ | |
7.92% | SEC ↗ | |
7.92% | SEC ↗ | |
7.92% | SEC ↗ | |
7.92% | SEC ↗ |
AtriCure Executives and Management Board
15 members · avg. age 59 · 40 % women
Mr. Michael Carrel (54)
President, Chief Executive Officer, Director · since 2012
11.07 M USD
Management
Mr. Douglas Seith (59)
Chief Operating Officer
Ms. Angela Wirick (47)
Chief Financial Officer
Mr. Karl Dahlquist (55)
Chief Legal Officer
Mr. Justin Noznesky (47)
Chief Marketing and Strategy Officer
Mr. Salvatore Privitera (58)
Chief Technical Officer
Dr. Vinayak Doraiswamy (53)
Chief Scientific Officer
Board of Directors
Mr. Shlomo Nachman (63)
Independent Director
Mr. Robert White (60)
Independent Chairman of the Board
Ms. B. Kristine Johnson (73)
Independent Director
Ms. Regina Groves (66)
Independent Director
Mr. Sven Wehrwein (74)
Independent Director
Ms. Karen Prange (61)
Independent Director
Frequently asked questions about AtriCure
AtriCure Inc is a medical device company specializing in the development and manufacturing of solutions for the treatment of atrial fibrillation and other cardiac disorders. The company's business model primarily revolves around the research, development, production, and commercialization of innovative technologies and surgical devices. By offering advanced cardiac ablation systems, surgical instruments, and related tools, AtriCure Inc aims to provide healthcare professionals with effective solutions for improving patient outcomes in the field of cardiac surgery. As a leading player in the medical device industry, AtriCure Inc embraces a customer-centric approach, focusing on delivering high-quality products and comprehensive support to healthcare providers globally.
AtriCure Inc is primarily active in the healthcare and medical device industries.
The main competitors of AtriCure Inc in the market include Medtronic plc, Boston Scientific Corporation, and Johnson & Johnson.
AtriCure Inc is a leading medical device company specializing in surgical ablation systems for the treatment of atrial fibrillation and other cardiac arrhythmias. Founded in 2000, AtriCure has been dedicated to advancing innovative technologies and techniques to deliver optimal patient outcomes. With a strong focus on research and development, the company has constantly evolved to provide state-of-the-art solutions for cardiac surgeons and patients. AtriCure's commitment to excellence has earned it a reputation as a trusted leader in the industry. Today, it continues to revolutionize the field of cardiac ablation with its comprehensive portfolio of products and a relentless pursuit of technological advancements.
AtriCure Inc, a leading medical device company, has achieved several significant milestones. Notably, the company received approval from the U.S. FDA for its AtriClip® System, a revolutionary device that aids in the prevention of stroke during open-heart surgeries. Additionally, AtriCure Inc has successfully expanded its international presence by obtaining regulatory approvals in Europe, Canada, and other countries for the AtriCure® EPi-Sense® System and other innovative products. Moreover, the company has witnessed considerable growth through strategic acquisitions, such as the purchase of SentreHEART, further enhancing its portfolio of advanced cardiac surgical solutions. These milestones highlight AtriCure Inc's commitment to pioneering advancements in surgical technologies to improve patient outcomes.
AtriCure Inc is primarily present in various countries and regions across the world. The company has a global presence with a focus on North America, Europe, and Asia. AtriCure operates in the United States, where its headquarters are based, and serves customers across the country. It also has a significant presence in European markets, including countries like Germany, France, the United Kingdom, and Italy. Additionally, AtriCure has been expanding its reach in Asia, including markets such as China, Japan, and South Korea. With its widespread presence, AtriCure Inc caters to a diverse range of customers globally.
AtriCure Inc represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company focuses on delivering groundbreaking solutions for the treatment of atrial fibrillation and other cardiac conditions. AtriCure Inc consistently strives to improve patient outcomes and enhance the quality of life through their innovative medical technologies. The company's commitment to research, development, and continuous improvement enables them to provide cutting-edge solutions that address the evolving needs of patients and healthcare providers. AtriCure Inc's dedication to excellence and patient care sets them apart in the medical device industry.
Analysts currently set an average price target of 52.33 USD for the AtriCure stock (median: 52.00 USD), implying -11.7 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the AtriCure stock: 13 recommend buying, 3 holding and 0 selling. For 2026, analysts expect AtriCure to generate revenue of 606.25 M USD and earnings per share of 0.11 USD.
Converted at the current exchange rate, the AtriCure share trades at 50.62 EUR (58.10 USD).
The AtriCure share (ATRC) is listed on 1 stock exchanges, including: NASDAQ (ATRC).
AtriCure Inc. is a medical company specializing in the development and sale of cardiology devices. The company offers a wide range of products that can be used for the treatment of heart diseases. The company is divided into three main segments: cardiology, surgery, and pacing. In the cardiology segment, AtriCure offers devices that can be used to restore normal heart rhythms. These devices are commonly used in patients with atrial fibrillation or other cardiac arrhythmias. The surgical segment of AtriCure focuses on the development of devices that can be used in heart surgeries. This includes instruments for tissue removal and devices to support the heart-lung circulation during the operation. The third segment of AtriCure is the pacing segment. Here, the company sells devices that can be used to regulate the heartbeat. They are typically used in patients with cardiac arrhythmias. One of AtriCure's most well-known products is the bipolar cutting and coagulation device. This device is commonly used in cardiac surgeries and allows surgeons to remove tissue quickly and precisely. Another product from AtriCure is the AtriClip system. This is a clip system that is used during heart surgery to close off the left atrium. This can help reduce the risk of atrial fibrillation after the operation. Overall, AtriCure has developed a wide range of medical devices tailored to the needs of cardiology and surgical patients. The company's products are known for their high quality and reliability. The company is constantly striving to develop new, innovative products that have the potential to improve the surgical treatment of heart diseases. An important part of AtriCure's business model is collaboration with other companies and institutions. The company works closely with clinicians, scientists, and companies in the medical industry to develop and test innovative products. To drive the company's growth, AtriCure has made a number of strategic acquisitions. For example, in 2019, the company acquired SentreHeart, which has developed an innovative procedure for the treatment of atrial fibrillation. Overall, AtriCure's business model is focused on continuous improvement and innovation. The company aims to develop high-quality products that can save lives and improve the treatment of heart diseases. AtriCure is continually working to build partnerships and drive the growth of the company to improve patient care in the cardiology community.
The expected revenue of AtriCure is 606.25 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of AtriCure is 5.32 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of AtriCure is currently 534.04. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the AtriCure stock.
The price-to-sales ratio (P/S) of AtriCure is currently 4.68. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the AtriCure stock.
The Eulerpool Quality Score for AtriCure is 2/10.
The ISIN of AtriCure is US04963C2098. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of AtriCure is A0ES9W. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of AtriCure is ATRC. The ticker symbol is used to trade AtriCure shares on the stock exchange.
AtriCure paid dividends every year for the past 0 years.
AtriCure is assigned to the 'Health' sector.
The dividends of AtriCure are distributed in USD.
AtriCure stock
AtriCure Peer Group
AtriCure Ticker
AtriCure FIGI
All fundamentals and in-depth analysis of AtriCure
Our stock analysis for AtriCure stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AtriCure. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.